Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Contineum TherapeuticsCTNM -1.37%17 Quick Ratio is 37.17 as of Jun. 2026, which is 60% above its 10-year median of 23.29. GuruFocus rates CTNM with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Contineum Therapeutics ranks better than 97.8% on this metric.
Contineum Therapeutics (NAS:CTNM) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Contineum Therapeutics Quick Ratio Related Terms
Contineum Therapeutics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Contineum Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Contineum Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Contineum Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Contineum Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Contineum Therapeutics (CTNM) has a Quick Ratio of 37.17 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Contineum Therapeutics and its competitors. This is 60% above median its historical median of 23.29. Over the past decade, Contineum Therapeutics' Quick Ratio has ranged from 6.41 to 58.92. According to the industry distribution chart, Contineum Therapeutics ranks #31 out of 1411 companies in the Biotechnology industry, placing it in the top 2.2%.
Is Contineum Therapeutics' Quick Ratio too high?
Contineum Therapeutics' current Quick Ratio of 37.17 is 60% above median its 10-year median of 23.29. Over the past 10 years, this metric has ranged from a low of 6.41 to a high of 58.92. The Biotechnology industry median Quick Ratio is 3.57. Contineum Therapeutics' value of 37.17 is 941.2% above this industry median. Based on the distribution chart, Contineum Therapeutics ranks #31 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Contineum Therapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Contineum Therapeutics' Quick Ratio compare to FDMT and PRME?
According to the Biotechnology industry distribution chart, Contineum Therapeutics ranks #31 out of 1411 companies for Quick Ratio. This places Contineum Therapeutics in the top 2% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.57. Contineum Therapeutics' value of 37.17 is 941.2% above this benchmark. Historically, Contineum Therapeutics' own Quick Ratio has ranged from 6.41 to 58.92 over the past decade. While the company's 10-year median is 23.29 vs. the industry median of 3.57, Contineum Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.57, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Contineum Therapeutics's current Quick Ratio of 37.17 is 941.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Contineum Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Contineum Therapeutics's current Quick Ratio is 37.17, which is 60% above median its own 10-year median of 23.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Contineum Therapeutics stock overvalued right now?
Contineum Therapeutics (CTNM) has a current Quick Ratio of 37.17. The current Quick Ratio is 37.17, which is 60% above median its 10-year median of 23.29 and 941.2% above the Biotechnology industry median of 3.57. Contineum Therapeutics' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Contineum Therapeutics (CTNM), the current Quick Ratio is 37.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
17GF Score
Get the complete analysis for CTNM
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTNM has been successfully added to your 
